Print this page

MEM INST OSWALDO CRUZ, RIO DE JANEIRO, 112(12) December 2017
PAGES: 829-837 DOI: 10.1590/0074-02760170182 Full paper
Dengue serotype-specific immune response in Aedes aegypti and Aedes albopictus

Chelsea T Smartt+, Dongyoung Shin, Barry W Alto

University of Florida, Department of Entomology and Nematology, Florida Medical Entomology Laboratory, Vero Beach, FL, USA

128 DOWNLOADS 151 VIEWS
Abstract

BACKGROUND Dengue viruses (DENV) are considered one of the most important emerging pathogens and dengue disease is a global health threat. The geographic expansion of dengue viruses has led to co-circulation of all four dengue serotypes making it imperative that new DENV control strategies be devised.

OBJECTIVES Here we characterize dengue serotype-specific innate immune responses in Aedes aegypti and Aedes albopictus using DENV from Puerto Rico (PR).

METHODS Ae. aegypti and Ae. albopictus were infected with dengue serotype 1 and 2 isolated from Puerto Rico. DENV infected mosquito samples were collected and temporal change in expression of selected innate immune response pathway genes analyzed by quantitative real time PCR.

FINDINGS The Toll pathway is involved in anti-dengue response in Ae. aegypti, and Ae. albopictus. Infections with PR DENV-1 elicited a stronger response from genes of the Toll immune pathway than PR DENV-2 in Ae. aegypti but in infected Ae. albopictus expression of Toll pathway genes tended to be similar between the serotypes. Two genes (a ribosomal S5 protein gene and a nimrod-like gene) from Ae. albopictus were expressed in response to DENV.

MAIN CONCLUSIONS These studies revealed a role for antiviral genes in DENV serotype-specific interactions with DENV vectors, demonstrated that infections with DENV-2 can modulate the Toll immune response pathway in Ae. aegypti and elucidated candidate molecules that might be used to interfere with serotype specific vector-virus interactions.

key words:

Financial support: Department of Agriculture and Consumer Services (DACS) 2010 (grant 00090369 to BWA and CTS), and partially by the National Institutes of Health Southeast Regional Center of Excellence for Emerging Infections & Biodefense (grant 5-U54-AI-057157-09 / UNC SERCEB) subcontract to CTS.
+ Corresponding author: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Received 9 May 2017
Accepted 21 June 2017